Comparison
Metformin vs Sermorelin
Side-by-side of Metformin and Sermorelin. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Metformin
Metformin for longevity: biguanide mechanism of action, TAME trial status, anti-aging dosage, weight loss data, life extension evidence in non-diabetics.
Sermorelin
Sermorelin peptide therapy uses a 29-amino-acid GHRH analog to raise endogenous GH. Dosing, half-life, sermorelin vs ipamorelin, and safety.
Effects at a glance
Metformin
- •Reduces HbA1c by ~1.0 to 1.5 percentage points in type 2 diabetes; first-line agent in major guidelines
- •DPP trial: 31% reduction in T2DM incidence in adults with prediabetes over 2.8 years
- •Suppresses hepatic gluconeogenesis via AMPK activation and complex I inhibition
- •Long-term use depletes B12; annual monitoring recommended after year 2
- •Lifespan extension in non-diabetic humans is not established; TAME trial pending
- •MASTERS trial reported blunted resistance-training hypertrophy in older adults
Sermorelin
- •Synthetic 29-amino-acid GHRH fragment; FDA approved 1997 for pediatric GH deficiency as Geref
- •Voluntarily discontinued by Serono in 2008 for commercial reasons; not safety-related
- •Compounded by 503A/503B pharmacies for off-label adult anti-aging and body-composition use
- •Produces physiologic pulsatile GH release; ~10 to 20 minute plasma half-life
- •Standard anti-aging clinic protocol: 200 to 500 mcg subcutaneously pre-bed, often with ipamorelin
- •Banned by WADA under S2 (peptide hormones, growth factors)
Side-by-side
| Attribute | Metformin | Sermorelin |
|---|---|---|
| Category | pharmaceutical | peptide |
| Also known as | Glucophage, Fortamet, Glumetza, dimethylbiguanide | Sermorelin acetate, GRF 1-29, Geref, GHRH (1-29) NH2 |
| Half-life (hr) ↗ | 6 | 0.25 |
| Typical dose (mg) ↗ | 1500 | 0.3 |
| Dosing frequency | 1 to 3 times daily with meals; XR once daily | 1-2x daily |
| Routes | oral | subcutaneous |
| Onset (hr) | 1 | 0.25 |
| Peak (hr) | 2.5 | 0.5 |
| Molecular weight | 129.16 | 3357.88 |
| Molecular formula | C4H11N5 | C149H246N44O42S |
| Mechanism | Suppresses hepatic gluconeogenesis primarily via AMPK activation and complex I inhibition; modestly improves peripheral insulin sensitivity and shifts gut microbiome composition. | Synthetic 29-amino-acid GHRH fragment that binds the GHRH receptor on pituitary somatotrophs to stimulate endogenous pulsatile GH synthesis and release while preserving the GH-IGF-1 negative feedback loop. |
| Legal status | Prescription only (FDA approved for type 2 diabetes 1994) | FDA approved 1997 (Geref, pediatric GHD); voluntarily discontinued by Serono 2008; compounded by 503A/503B pharmacies for off-label adult use; banned by WADA |
| WADA status | allowed | banned |
| DEA / Rx | Rx only (not a controlled substance) | Rx only via compounding (no controlled-substance schedule) |
| Pregnancy | Category B; used in gestational diabetes and PCOS per current guidance | Category C (historical labeling); not recommended in pregnancy |
| CAS | 657-24-9 | 86168-78-7 |
| PubChem CID | 4091 | 16129617 |
| Wikidata | Q19484 | Q416620 |
Safety profile
Metformin
Common side effects
- nausea
- diarrhea
- abdominal discomfort
- metallic taste
- decreased appetite
- B12 depletion (long-term)
Contraindications
- eGFR below 30 mL/min/1.73m2
- acute or chronic metabolic acidosis
- severe hepatic impairment
- acute heart failure
- iodinated contrast within 48 hours
Interactions
- iodinated contrast media: renal injury risk; hold 48 hours peri-imaging(major)
- alcohol (heavy use): elevated lactic acidosis risk(major)
- cimetidine: raises metformin plasma levels via OCT2 inhibition(moderate)
- insulin and sulfonylureas: additive hypoglycemia risk in combination(moderate)
- dolutegravir: raises metformin exposure via OCT2(moderate)
Sermorelin
Common side effects
- injection-site pain or irritation
- transient flushing
- headache
- vivid dreams (pre-bed dosing)
Contraindications
- pregnancy
- active malignancy
- history of pituitary tumor
- diabetic retinopathy (theoretical)
- untreated hypothyroidism
Interactions
- ipamorelin: synergistic GH release via parallel GHRH and ghrelin pathways; standard anti-aging clinic pairing(minor)
- CJC-1295: pharmacologically redundant (both GHRH-pathway); typically not stacked(minor)
- insulin: sustained GH can blunt insulin sensitivity over weeks(moderate)
- corticosteroids: blunt GH response; reduce expected efficacy(moderate)
- levothyroxine (untreated hypothyroidism): untreated hypothyroidism blunts GH response; correct thyroid first(moderate)
Which Should You Take?
Metformin and Sermorelin score evenly on the criteria we weight (goal breadth, legal accessibility, evidence depth). The conditionals below should drive the decision more than any aggregate score.
- → If your priority is metabolic health and glucose control, pick Metformin.
- → If your priority is growth-hormone axis, pick Sermorelin.
- → If your priority is post-training recovery, pick Sermorelin.
Edge case: If you cannot self-administer injections, Metformin is the only oral option in this pair.
Default choice: either is defensible. Metformin edges out on goal breadth + legal accessibility; Sermorelin is the right call if your priority sits in the goals listed above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Metformin and Sermorelin?
Metformin and Sermorelin differ in category (pharmaceutical vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Metformin or Sermorelin?
Metformin half-life is 6 hours; Sermorelin half-life is 0.25 hours.
Can you stack Metformin with Sermorelin?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper